Fragment-based drug discovery: what really works. An interview with Sandy Farmer of Boehringer Ingelheim

  • Wendy A. WarrEmail author
Warr's Piece
Sandy Farmer holds an M. Sc. and Ph.D. in Biophysical Chemistry from the University of Kentucky (1984), and an MBA in Pharmaceutical Studies from Fairleigh Dickinson University (1997). As the Director of Structural Research at Boehringer Ingelheim Pharmaceuticals (2001–2010), he co-led the global, multi-disciplinary drug-discovery team (2004–2010) that has developed fragment-based drug discovery into a mainstream lead generation activity at Boehringer Ingelheim. In late 2010, he became head of IT Business Partnering for Research, Development and Medicine within the United States, in which capacity he oversees many of the IT application and system developments that will further contribute to an even broader array of lead generation and optimization initiatives and efforts within Boehringer Ingelheim worldwide.


Nuclear Magnetic Resonance Surface Plasmon Resonance Fluorescence Polarization Lead Candidate Fragment Element 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Warr WA (2009) J Comput Aided Mol Des 23:453–458CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  1. 1.Wendy Warr & AssociatesCheshireEngland

Personalised recommendations